Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are two stocks where Wall Street’s pessimism is creating a buying opportunity and one where the skepticism is well-placed.
One Stock to Sell:
Merck (MRK)
Consensus Price Target: $156.36 (12% implied return)
With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck (NYSE:MRK) develops and sells prescription medicines, vaccines, and animal health products across oncology, infectious diseases, cardiovascular, and other therapeutic areas.
Why Does MRK Worry Us?
- Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn’t resonate with customers
- Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 19.9 percentage points
- Earnings per share fell by 11.1% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
Merck’s stock price of $139.65 implies a valuation ratio of 16.9x forward P/E. Dive into our free research report to see why there are better opportunities than MRK.
Two Stocks to Watch:
Pfizer (PFE)
Consensus Price Target: $28.91 (5.4% implied return)
With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions.
Why Do We Like PFE?
- Unparalleled scale of $63.7 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
- Adjusted operating profits and efficiency rose over the last two years as it benefited from some fixed cost leverage
- Industry-leading 17.5% return on capital demonstrates management’s skill in finding high-return investments
Pfizer is trading at $27.43 per share, or 10x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
Federated Hermes (FHI)
Consensus Price Target: $61 (7.5% implied return)
With roots dating back to 1955 and a pioneering role in money market funds, Federated Hermes (NYSE:FHI) is an investment management firm that offers a wide range of funds and strategies for institutional and individual investors.
Why Is FHI a Good Business?
- Products and services resonate with customers, evidenced by its respectable 10.2% annualized sales growth over the last two years
- Share buybacks propelled its annual earnings per share growth to 21.1%, which outperformed its revenue gains over the last two years
- Stellar return on equity showcases management’s ability to surface highly profitable business ventures
At $56.75 per share, Federated Hermes trades at 9.7x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.